Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 9/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.35 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910211 | 0.84 | CSF1R (0.60) | CSF1RKITCYP2C9 | |
| SCHEMBL2907600 | 0.83 | CSF1R (0.64) | CSF1RKITCYP2C9 | |
| SCHEMBL3093595 | 0.81 | CSF1R (0.62) | CSF1RKITCYP2C9TLR9TLR8 | |
| Trifluoroacetic Acid SCHEMBL2935046 | 0.80 | CSF1R (0.49) | CSF1RKITCYP2C9TLR9TLR8 | |
| Trifluoroacetic Acid SCHEMBL16594286 | 0.79 | CSF1R (0.67) | CSF1RKITCYP2C9 | |
| SCHEMBL2941502 | 0.77 | CSF1R (0.54) | CSF1RKITCYP2C9TLR9TLR8 | |
| SCHEMBL13096401 | 0.77 | CSF1R (0.73) | CSF1RKITCYP2C9 | |
| SCHEMBL13179403 | 0.77 | CSF1R (0.66) | CSF1RKITCYP2C9 | |
| SCHEMBL13981695 | 0.75 | QDPR (0.54) | CSF1RCYP2C9TLR9TLR8TLR7 | |
| SCHEMBL13523798 | 0.70 | CSF1R (0.62) | CSF1RKITCYP2C9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | CSF1R 3/4885KIT 70/4885CYP2C9 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.